• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Immune camouflage: Relevance to vaccines and human immunology

Immune camouflage: Relevance to vaccines and human immunology

by Annie De Groot | Jan 13, 2020

De Groot et al. – 2014 – Immune camouflage Relevance to vaccines and human immunology
The two-faced T cell epitope: Examining the host-microbe interface with JanusMatrix

The two-faced T cell epitope: Examining the host-microbe interface with JanusMatrix

by Adam | Oct 22, 2016

Hum Vaccin Immunother. 2013 Apr 12;9(7). PubMed PMID 23584251
Integrated assessment of predicted MHC binding and cross-conservation with self reveals patterns of viral camouflage

Integrated assessment of predicted MHC binding and cross-conservation with self reveals patterns of viral camouflage

by Adam | Oct 22, 2016

BMC Bioinformatics 2014, 15 (Suppl 4): S1 doi:10.1186/1471-2105-15-S4-S1.
Development and validation of an epitope prediction tool for swine (PigMatrix) using the pocket profile method

Development and validation of an epitope prediction tool for swine (PigMatrix) using the pocket profile method

by Adam | Oct 22, 2016

BMC Bioinformatics. BMC Bioinformatics. 2015 Sep 15;16(1):290. doi: 10.1186/s12859-015-0724-8.
Hit-and-run, hit-and-stay, and commensal bacteria present different peptide content when viewed from the perspective of the T cell

Hit-and-run, hit-and-stay, and commensal bacteria present different peptide content when viewed from the perspective of the T cell

by Adam | Oct 22, 2016

Vaccine. 2015 Oct 1. doi: 10.1016/j.vaccine.2015.08.099
« Older Entries

Recent Posts

  • The Platinum Vaccine & Change is Good!
  • EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO
  • Smarter Tools, Safer Therapies: Supporting the FDA’s Roadmap with in silico Immunogenicity Assessment
  • The Amsterdam Immunogenicity & Tolerance Seminar: 2025
  • The Westin Immunogenicity Seminar

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CMO, Dr. Annie De Groot.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.